Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5469311> ?p ?o }
Showing triples 1 to 32 of
32
with 100 triples per page.
- Q5469311 subject Q52376.
- Q5469311 subject Q7116685.
- Q5469311 subject Q7204516.
- Q5469311 subject Q8431759.
- Q5469311 subject Q8878163.
- Q5469311 subject Q9052323.
- Q5469311 abstract "Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical trials have been run. As of Template:MONTHNAME 2015[[Category:Articles containing potentially dated statements from Template:MONTHNAME 2015]] no phase III trials are registered.Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).".
- Q5469311 iupacName "N1’-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide".
- Q5469311 thumbnail Foretinib.svg?width=300.
- Q5469311 wikiPageWikiLink Q14875866.
- Q5469311 wikiPageWikiLink Q18028241.
- Q5469311 wikiPageWikiLink Q212322.
- Q5469311 wikiPageWikiLink Q4356503.
- Q5469311 wikiPageWikiLink Q5005894.
- Q5469311 wikiPageWikiLink Q52376.
- Q5469311 wikiPageWikiLink Q5419989.
- Q5469311 wikiPageWikiLink Q7116685.
- Q5469311 wikiPageWikiLink Q7204516.
- Q5469311 wikiPageWikiLink Q795057.
- Q5469311 wikiPageWikiLink Q8431759.
- Q5469311 wikiPageWikiLink Q8878163.
- Q5469311 wikiPageWikiLink Q9052323.
- Q5469311 wikiPageWikiLink Q906415.
- Q5469311 iupacname "N1’-[3-fluoro-4-[[6-methoxy-7--4-quinolyl]oxy]phenyl]-N1-cyclopropane-1,1-dicarboxamide".
- Q5469311 type ChemicalCompound.
- Q5469311 type ChemicalSubstance.
- Q5469311 type ChemicalObject.
- Q5469311 type Thing.
- Q5469311 type Q11173.
- Q5469311 comment "Foretinib is an experimental drug candidate for the treatment of cancer. It was discovered by Exelixis and is under development by GlaxoSmithKline. About 10 Phase II clinical trials have been run. As of Template:MONTHNAME 2015[[Category:Articles containing potentially dated statements from Template:MONTHNAME 2015]] no phase III trials are registered.Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).".
- Q5469311 label "Foretinib".
- Q5469311 depiction Foretinib.svg.